PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 13, 2005New England Journal of Medicine5,468 citationsOpen Access

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

View Full Paper
FSFrances A. ShepherdJPJosé Rodrigues PereiraTCTudor–Eliade Ciuleanu

Key Points

Key points are not available for this paper at this time.

Abstract

Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Shepherd et al. (2005) studied this question.

synapsesocial.com/papers/69deab246bae133e7de948b5https://doi.org/10.1056/nejmoa050753
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome2005 · 1,857 citations
  2. 2High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan2004 · 553 citations
  3. 3EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy2004 · 9,459 citations
  4. 4Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials1996 · 2,517 citations
  5. 5Severe acute interstitial pneumonia and gefitinib2003 · 458 citations